| scholarly article | Q13442814 |
| P50 | author | Raymond L. Woosley | Q7298947 |
| P2093 | author name string | Werner P | |
| Taylor L | |||
| Cohen-Mansfield J | |||
| Lipson S | |||
| Billig N | |||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | haloperidol | Q251347 |
| lorazepam | Q408265 | ||
| P304 | page(s) | 1733-1740 | |
| P577 | publication date | 1999-08-01 | |
| P1433 | published in | JAMA Internal Medicine | Q177428 |
| P1476 | title | Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study | |
| P478 | volume | 159 |
| Q36937252 | A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease |
| Q92855019 | A Scoping Review Mapping Research on Green Space and Associated Mental Health Benefits |
| Q21144654 | A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial) |
| Q34316513 | A systematic mapping review of randomized controlled trials (RCTs) in care homes |
| Q32090982 | Antipsychotic medications and the elderly: effects on cognition and implications for use. |
| Q37777746 | Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality |
| Q49113515 | Barriers to antipsychotic discontinuation in nursing homes: an exploratory study |
| Q33536593 | Changes to psychotropic medications in the six months after admission to nursing homes in Melbourne, Australia |
| Q35086756 | Correlates of behavioral disturbances and pattern of psychotropic medication use in five skilled nursing facilities |
| Q34558884 | Dementia prevention, intervention, and care. |
| Q39102518 | Documentation of antipsychotic use and indications for newly diagnosed, nonaggressive dementia patients |
| Q91699759 | Effects of discontinuation of chronic medication in primary care: a systematic review of deprescribing trials |
| Q51867898 | Fifteen year comparison of antipsychotic use in people with dementia within hospital and nursing home settings: sequential cross-sectional study. |
| Q34580523 | Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units |
| Q35093389 | Increase in drug use after admission to Dutch nursing homes |
| Q37504709 | Management of agitation and aggression associated with Alzheimer disease |
| Q37680018 | Management of behavioral problems in Alzheimer's disease |
| Q33949205 | Medication safety in residential aged-care facilities: a perspective |
| Q37330303 | Medication withdrawal trials in people aged 65 years and older: a systematic review. |
| Q37804536 | Memantine Discontinuation and the Health Status of Nursing Home Residents With Alzheimer's Disease |
| Q81825183 | Neuroleptic discontinuation during dementia care: a recent trial and its implications for practice |
| Q36484553 | Neuroleptic drugs in dementia: benefits and harm |
| Q37299919 | Neuropsychiatric symptoms in dementia: importance and treatment considerations. |
| Q37004363 | Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease |
| Q53283588 | Pharmacological interventions for apathy in Alzheimer's disease. |
| Q57689410 | Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users |
| Q34452896 | Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review |
| Q43001958 | Placebo by proxy |
| Q39163974 | Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations |
| Q37851459 | Prevalence and management of behavioural and psychiatric symptoms on a continuing care unit for patients with dementia |
| Q33562417 | Psychiatric Aspects of Dementia |
| Q34634559 | Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem |
| Q24682986 | Recognition and Management of Behavioral Disturbances in Dementia |
| Q36375421 | Relapse risk after discontinuation of risperidone in Alzheimer's disease |
| Q37820701 | Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems |
| Q46729093 | Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS). |
| Q35136544 | The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design |
| Q51867401 | The course of behavioral problems in elderly nursing home patients with dementia when treated with antipsychotics. |
| Q34920191 | The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial |
| Q49155808 | The effects of abrupt antipsychotic discontinuation in cognitively impaired older persons: a pilot study |
| Q34522113 | The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. |
| Q40099193 | The use of antipsychotics among people treated with medications for dementia in residential aged care facilities |
| Q24198248 | Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia |
| Q37762792 | Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? |
Search more.